Cardiac Amyloidosis
Conditions
Brief summary
1. Patients will undergo clinical and laboratory assessment, as well as imaging tests, at the discretion of the attending cardiologist and will be referred at their discretion to perform cardiac mapping using 99mTc-PYP. 2. On the day of the examination, the examiner will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Before conducting the test, the subject will undergo a brief interview by a physician, receive an explanation of the study and, if agreed, sign an agreement to perform a further examination on the CZT camera. 3. The patient will, as is customary, be installed on Vanflon 22 G periphery, through which a 15 millikiric (mCi) of
Interventions
DIAGNOSTIC_TESTSpect scan with mTc99-PYP
. About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.
Sponsors
Tel-Aviv Sourasky Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
A. Patients undergoing cardiac amyloidosis clinic at Tel Aviv Medical Center and there is a clinical suspicion of having cardiac amyloidosis. B. Patients who performed will be referred for mapping using 99mTc-PYP and sign a consent form to take another photograph, under the cardiac-dedicated CZT camera
Exclusion criteria
1.None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients who preformed mTc99-PYP for cardiac amyloidosis imaging. | 1 year | Evaluation of cardiac amyloidosis imaging with mTc99-PYP cardiac-dedicated CZT camera |
Outcome results
None listed